New standards concerning patient safety and confusion over regulatory requirements have caused a drop in India's clinical drug trials, from 500 in 2010 to 262 in 2012, with only 56 such trials approved this year, The Wall Street Journal has reported. Drug companies are running 2,247 trials in India, about half the number underway in China and South Korea. "If we do not have a conductive environment, companies ... will be forced to take these studies to other global markets outside India," said Biocon founder Kiran Mazumdar Shaw.

Full Story:

Related Summaries